查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837228

按适应症、技术平台、给药途径、分销管道和最终用户分類的治疗性疫苗市场—2025-2032年全球预测

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，治疗性疫苗市场规模将达到 746.5 亿美元，复合年增长率为 10.72%。

关键市场统计数据
基准年2024年 330.5亿美元
预计年份：2025年 366亿美元
预测年份 2032 746.5亿美元
复合年增长率 (%) 10.72%

一个整合科学进步、监管变化和相关人员期望的策略框架，旨在指导治疗性疫苗领域的决策者。

在科学进步和不断变化的商业性格局的驱动下，治疗性疫苗领域正在经历一场变革。抗原发现、免疫调节和递送技术的最新进展，已使治疗性疫苗从一项小众科学研究发展成为涵盖癌症、感染疾病、自体免疫疾病和神经系统疾病等多种适应症的策略性疗法。本导言概述了影响研发人员、製造商和相关人员近期策略重点的核心科学原理、法规环境和相关人员期望。

临床医师和经营团队正面临一个复杂的环境：精准免疫标靶技术日益成熟，同时，包括核酸构建体、病毒载体和细胞製剂在内的先进平台技术也不断发展。同时，监管机构也正在完善疗效终点、真实世界证据整合和适应症核准机制的证据路径，这些都将影响产品开发时间表和上市策略。综上所述，这些动态变化既带来了机会，也带来了责任：设计能够证明持续临床效用的临床试验，投资于可扩展的生产，并製定能够体现患者和医疗保健系统长期价值的定价和准入模式。

因此，要理解治疗性疫苗，需要从多角度出发：适应症特异性生物学、平台能力、给药和分发实际情况，以及相关人员接受度的经济影响。本执行摘要阐述了这个观点，并为读者深入分析产业转型、政策影响、市场区隔影响、区域动态、竞争格局以及可操作的建议奠定了基础。

重大的技术、监管和生产变革正在重新定义治疗性疫苗的研发路径和商业策略。

治疗性疫苗领域正再形成一系列变革性转变，这些转变将改变产品的研发、生产、监管和商业化方式。 mRNA和自扩增RNA平台的技术加速发展，以及脂质奈米颗粒递送技术的改进和抗原筛选方法的进步，正在缩短从发现到首次人体接种的时间。同时，病毒载体工程和全细胞或树突细胞策略正在拓展治疗范围，使其覆盖先前难以攻克的疾病，尤其是在肿瘤学和复杂感染疾病。这些平台的进步使得更精准的免疫编程和联合治疗策略成为可能，例如将疫苗与查核点抑制剂或标靶治疗结合，从而提高疗效。

法律规范也在同步调整，以适应适应性试验设计、替代终点和以有意义的临床结果为重点的加速路径。支付方和医疗系统日益要求强有力的价值证明，包括疗效的持久性和后续成本抵消，这促使研发人员从研发的早期阶段就将卫生经济学和结果研究纳入其中。此外，模组化设施、一次性生物製程和分散式生产模式等製造创新降低了规模化生产的技术门槛，同时也提高了对供应链韧性和品质保证的期望。

总而言之，这些转变正在推动一种新的产业架构的形成，在这种架构中，多学科协作、灵活的监管互动和策略性的製造投资决定了竞争优势。那些能够将科学抱负与切实可行的商业化计划和相关人员参与相结合的组织，将更有能力把免疫学方面的进展转化为对患者有意义的影响和永续的商业性成果。

美国关税政策将于2025年生效，其变化将如何影响治疗性疫苗开发商的供应链策略、生产在地化和采购惯例？

美国2025年实施的关税政策变化所带来的累积效应，为治疗性疫苗的相关人员在采购、生产和供应决策方面带来了新的考量。某些生技药品原料和组件的进口关税提高，推高了关键原料的成本，包括用于奈米颗粒载体的脂质、质体DNA生产原料以及病毒载体生产中使用的特殊试剂。因此，供应链规划正转向更加重视供应商多元化和策略性库存管理，以降低价格波动和潜在的运输中断风险。

为因应关税带来的成本压力，一些开发商正加快推动生产营运在地化，并认证国内合约开发和受託製造厂商，以减轻跨境关税的影响。这一转变影响了资本配置和前置作业时间管理，因为建造或改造设施需要大量的营运规划。此外，采购团队正在重新评估筹资策略和总落地成本分析，以纳入关税的影响，以及运输、低温运输物流和监管合规等方面的成本。

监管机构和商业相关人员也积极应对这些贸易政策的影响。支付方和合约实体正在更严格地审查成本投入，这凸显了早期进行卫生经济建模和透明的供应成本核算的重要性。政策的不确定性促使各方更加关注多源采购、关键投入的策略性储备以及研发人员和生产合作伙伴之间的风险共担机制。最终，2025年的关税情况凸显了建立具有韧性的供应链、采取积极主动的筹资策略以及製定符合政策的商业计划对于保障专案进度和患者用药的重要性。

将适应性生物学、平台选择、给药途径、分销管道和最终用户实际情况与策略专案设计联繫起来的深度细分洞察

针对不同细分市场的动态变化驱动着治疗性疫苗计画在临床、监管和商业策略上的差异化，适应症、平台、给药途径、分销管道和最终用户等因素都会影响研发方案的选择。不同适应症的研发重点也有显着差异。在自体免疫疾病领域，我们将重点放在那些以抗原特异性耐受性和免疫调节为优先事项的疾病，例如红斑性狼疮、多发性类风湿性关节炎、类风湿性关节炎和第1型糖尿病；在感染疾病领域，我们优先关注鉅细胞病毒（CMV）、肝炎病毒、爱滋病毒（HIV） 、人类乳突病毒（HPV）和流感病毒等病原体，并将彻底清除病毒和持久控製作为核心终点；在神经系统疾病领域，我们致力于阿兹海默症、肌萎缩侧索硬化症、癫痫和帕金森氏症，并将血脑障壁穿透和神经发炎调节作为关键的科学挑战。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的基于mRNA的治疗性疫苗平台，针对个人化肿瘤新抗原以增强免疫抗原性
  • 利用奈米颗粒载体整合新型佐剂递送系统以增强疫苗诱发的免疫反应
  • 开发结合治疗性疫苗和免疫查核点抑制剂的联合治疗以克服肿瘤抗药性
  • 将人工智慧融入表位预测工作流程，以加速候选疫苗的设计。
  • 利用 CRISPR 基因编辑技术扩增预製同种异体树突细胞疫苗，以递送抗原
  • 基于IND和BLA框架的治疗性疫苗加速核准监管路径的演变
  • 探索异源初免-加强免疫策略以提高疫苗介导免疫的持久性和扩散性
  • 策略性生物技术联盟增加大型製药公司对治疗性疫苗研发管线的投资

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的治疗性疫苗市场

  • 自体免疫疾病
    • 狼疮
    • 多发性硬化症
    • 类风湿性关节炎
    • 1型糖尿病
  • 癌症
    • 乳癌
    • 子宫颈癌
    • 大肠直肠癌
    • 黑色素瘤
    • 摄护腺癌
  • 感染疾病
    • CMV
    • 肝炎
    • HIV
    • HPV
    • 流感
  • 神经系统疾病
    • 阿兹海默症
    • 肌萎缩侧索硬化症
    • 癫痫
    • 帕金森氏症

9. 治疗性疫苗市场－技术平台

  • 树突状细胞
  • DNA
    • 质体
  • 胜肽
  • RNA
    • mRNA
    • 自扩增RNA
  • 病毒载体
    • 腺病毒
    • 慢病毒
    • 牛痘病毒
  • 全细胞

第十章 依给药途径分類的治疗性疫苗市场

  • 皮内注射
  • 肌肉注射
  • 静脉
  • 皮下

第十一章 按分销管道分類的治疗性疫苗市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终用户分類的治疗性疫苗市场

  • 诊所
  • 医院
  • 研究所

第十三章 各地区治疗性疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的治疗性疫苗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国治疗性疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Moderna, Inc.
    • BioNTech SE
    • Bavarian Nordic A/S
    • Agenus Inc.
    • Inovio Pharmaceuticals, Inc.
    • Dendreon Pharmaceuticals LLC
    • GeoVax Labs, Inc.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market is projected to grow by USD 74.65 billion at a CAGR of 10.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.05 billion
Estimated Year [2025] USD 36.60 billion
Forecast Year [2032] USD 74.65 billion
CAGR (%) 10.72%

A strategic framing that synthesizes scientific progress, regulatory shifts, and stakeholder expectations to orient decision-makers in the therapeutic vaccines sector

The therapeutic vaccines landscape is at an inflection point driven by converging scientific advances and evolving commercial dynamics. Recent progress in antigen discovery, immune modulation, and delivery technologies has transformed therapeutic vaccines from a niche scientific pursuit into a strategic modality across oncology, infectious disease, autoimmune disorders, and neurological indications. This introduction frames the core scientific rationale, regulatory environment, and stakeholder expectations that collectively shape near-term strategic priorities for developers, manufacturers, and payers.

Clinicians and executives are navigating a complex environment in which precision immunologic targeting is maturing alongside sophisticated platform technologies such as nucleic acid-based constructs, viral vectors, and cell-based formulations. Meanwhile, regulatory authorities are refining evidentiary pathways for efficacy endpoints, real-world evidence integration, and adaptive approval mechanisms, which influences product development timelines and launch strategies. Taken together, these dynamics create both opportunity and responsibility: to design trials that demonstrate durable clinical benefit, to invest in scalable manufacturing, and to construct pricing and access models that reflect long-term value for patients and health systems.

Consequently, understanding therapeutic vaccines requires a multidimensional lens that spans indication-specific biology, platform capabilities, administration and distribution realities, and the stakeholder economics that determine adoption. This executive summary establishes that lens and prepares the reader for deeper analysis of transformative industry shifts, policy influences, segmentation implications, regional dynamics, competitive behavior, and actionable recommendations.

Major technological, regulatory, and manufacturing shifts are converging to redefine development pathways and commercial strategies for therapeutic vaccines

The therapeutic vaccines arena is being reshaped by a series of transformative shifts that alter how products are developed, manufactured, regulated, and commercialized. Technological acceleration in mRNA and self-amplifying RNA platforms, coupled with improved lipid nanoparticle delivery and refined antigen selection methods, is compressing timelines from discovery to first-in-human studies. At the same time, viral vector engineering and whole cell or dendritic cell strategies are expanding therapeutic reach into indications previously deemed intractable, particularly within oncology and complex infectious diseases. These platform advances are enabling more precise immune programming and combination strategies that pair vaccines with checkpoint inhibitors or targeted therapies to enhance efficacy.

Regulatory frameworks are adapting in parallel to accommodate adaptive trial designs, surrogate endpoints, and expedited pathways focused on meaningful clinical outcomes. Payers and health systems are increasingly demanding robust value demonstration, encompassing durability of response and downstream cost offsets, which is steering developers toward integrated health economics and outcomes research early in development. Additionally, manufacturing innovation-such as modular facilities, single-use bioprocessing, and decentralized production models-is reducing technical barriers to scale while raising expectations for supply chain resilience and quality assurance.

Taken together, these shifts are driving a new industry architecture in which cross-disciplinary collaboration, flexible regulatory engagement, and strategic manufacturing investments determine competitive differentiation. Organizations that align scientific ambition with pragmatic commercialization planning and stakeholder engagement will be best positioned to translate immunologic advances into meaningful patient impact and sustainable commercial outcomes.

How shifts in US tariff policy enacted in 2025 are influencing supply chain strategies, manufacturing localization, and procurement practices across therapeutic vaccine developers

The cumulative effect of tariff policy changes implemented in the United States in 2025 has introduced a new set of considerations for therapeutic vaccine stakeholders that extend across sourcing, manufacturing, and procurement decisions. Increased import tariffs on certain biologics inputs and components have elevated the cost of critical raw materials such as lipids for nanoparticle carriers, plasmid DNA production inputs, and specialty reagents used in viral vector manufacturing. As a result, supply chain planning has moved toward greater emphasis on supplier diversification and strategic inventory management to mitigate price volatility and potential shipment disruptions.

In response to tariff-driven cost pressures, some developers have accelerated initiatives to localize manufacturing operations and qualify domestic contract development and manufacturing organizations to reduce exposure to cross-border duties. This shift has implications for capital allocation and lead-time management, as building or repurposing facilities requires significant operational planning. Moreover, procurement teams are re-evaluating sourcing strategies and total landed cost analyses to incorporate tariff implications alongside transportation, cold chain logistics, and regulatory compliance overhead.

Regulatory and commercial stakeholders are also adapting to these trade policy effects. Payers and contracting entities are scrutinizing cost inputs more closely, which reinforces the need for early health economic modeling and transparent supply cost narratives. Policy uncertainty has increased interest in multi-sourcing, strategic stockpiles for critical inputs, and collaborative risk-sharing agreements between developers and manufacturing partners. Ultimately, the 2025 tariff landscape underscores the importance of resilient supply chains, proactive procurement strategies, and policy-aware commercial planning to preserve program timelines and patient access.

Deep segmentation insights that connect indication biology, platform selection, administration routes, distribution channels, and end-user realities to strategic program design

Segment-specific dynamics drive differentiated clinical, regulatory, and commercial strategies across therapeutic vaccine programs, with indication, platform, administration route, distribution channel, and end-user considerations each shaping development choices. Based on indication, development focus varies widely: autoimmune diseases target conditions such as lupus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes where antigen-specific tolerance and immune modulation are priorities; cancer programs concentrate on tumor types including breast, cervical, colorectal, melanoma, and prostate cancer where neoantigen targeting and combination regimens are critical; infectious disease efforts prioritize pathogens such as CMV, hepatitis viruses, HIV, HPV, and influenza where sterilizing immunity or durable control are the central endpoints; and neurological disorder initiatives address Alzheimer's disease, amyotrophic lateral sclerosis, epilepsy, and Parkinson's disease where blood-brain barrier delivery and neuroinflammation modulation are key scientific hurdles.

Based on technology platform, the choice between dendritic cell approaches, DNA platforms (including plasmid constructs), peptide vaccines, RNA platforms (comprising mRNA and self-amplifying RNA), viral vectors (including adenovirus, lentivirus, and vaccinia virus), and whole cell formulations materially alters manufacturing, regulatory engagement, and clinical trial design. RNA platforms typically demand advanced cold chain and delivery technologies, DNA plasmid workflows emphasize high-quality plasmid production and transfection strategies, and viral vector modalities require containment, potency assays, and specialized viral vector analytics. Dendritic cell and whole cell approaches often necessitate individualized or semi-personalized manufacturing workflows and close coordination with clinical sites.

Based on administration route, intradermal, intramuscular, intravenous, and subcutaneous delivery choices influence patient experience, dosing schedules, and the logistical footprint required for outpatient or inpatient administration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies present distinct fulfillment, storage, and reimbursement considerations that affect launch planning and patient access pathways. Based on end user, clinics, hospitals, and research institutes differ in procurement processes, clinical capabilities, and infrastructure readiness for specialized administration or investigational product handling. Integrating these segmentation layers into program planning enables sponsors to tailor clinical protocols, manufacturing scale, commercial access strategies, and stakeholder engagement plans to the realities of each therapeutic context.

Region-specific dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape regulatory strategy, manufacturing decisions, and market access planning

Regional dynamics exert powerful influence over development priorities, regulatory strategy, and commercialization pathways, necessitating region-aware planning across the Americas, Europe Middle East and Africa, and Asia-Pacific markets. In the Americas, strong innovation ecosystems, robust venture and corporate investment, and established regulatory frameworks encourage rapid clinical development and public-private partnerships, while payer systems vary, prompting developers to design flexible evidence-generation plans that support diverse reimbursement models. The region also hosts significant manufacturing capacity and a dense network of contract development and manufacturing organizations, which supports efforts to localize production and reduce supply chain exposure.

The Europe, Middle East and Africa region presents a complex mosaic of regulatory agencies, health technology assessment processes, and access landscapes. In many European markets, stringent value demonstration and centralized or coordinated procurement mechanisms require early alignment with health technology assessment bodies and multi-country clinical strategies. Regulatory convergence initiatives alongside regional centers of excellence for clinical trials and manufacturing present opportunities for strategic partnerships, but developers must navigate diverse reimbursement timelines and pricing pressures.

The Asia-Pacific region combines rapid clinical trial enrollment capacity, emerging manufacturing scale, and variable regulatory maturity. Several jurisdictions are accelerating regulatory reforms to facilitate innovative therapies, while others maintain more conservative pathways that demand localized data. Cost-conscious payers and rapidly growing healthcare infrastructure in certain markets create both challenges and opportunities for differentiated market-entry strategies. For all regions, cross-border collaborations, regional manufacturing hubs, and adaptive regulatory engagement strategies can optimize clinical timelines, improve supply reliability, and enhance patient access outcomes.

How corporate strategies and partnerships among leading companies are aligning platform specialization with manufacturing scalability and payer-focused evidence generation

Competitive behavior and corporate strategy among key companies in the therapeutic vaccines ecosystem reflect diversification across platforms, targeted indication portfolios, and strategic partnerships that bridge research, manufacturing, and commercialization capabilities. Leading organizations are pursuing platform consolidation to leverage core R&D investments across multiple indications, while others specialize in niche modalities such as dendritic cell therapies or viral vector engineering to capture scientific differentiation. Cross-sector alliances between biotechnology companies, academic centers, and contract manufacturers are increasingly common, aimed at accelerating translational work and ensuring supply chain capacity for clinical and commercial scale.

Partnership models vary from early-stage collaborations that co-develop antigen constructs and delivery systems, to later-stage licensing or commercialization agreements that align global go-to-market strategies. Manufacturers and service providers are investing in modular and flexible capacity to support heterogeneous product types-ranging from nucleic acid constructs requiring tight cold chain to cell-based products requiring individualized processing. In addition, some companies are integrating digital health and patient support solutions into launch plans to simplify administration logistics, monitor outcomes, and demonstrate real-world value.

Competitive differentiation also stems from regulatory acumen and payer engagement. Firms that proactively build robust health economic dossiers, engage with regulators on adaptive evidence pathways, and deploy early access programs are better positioned to secure favorable reimbursement arrangements and rapid uptake. Collectively, company strategies are converging on the need for end-to-end capabilities that link scientific innovation with scalable manufacturing, regulatory foresight, and commercially viable access models.

Practical and prioritized actions for developers and manufacturers to secure supply resilience, streamline regulatory engagement, and prove long-term value to payers and patients

Industry leaders should adopt a set of actionable priorities that balance scientific ambition with operational resilience and payer-oriented evidence generation. First, diversify supplier networks for critical inputs and prioritize qualification of alternate manufacturers to mitigate trade-related and single-source risks. Investing in regional manufacturing capacity or strategic partnerships can reduce exposure to cross-border policy changes while shortening lead times for clinical and commercial supply.

Second, integrate health economics and outcomes research into development programs from early phases to ensure that clinical trial design captures endpoints meaningful to regulators and payers alike. Employ adaptive trial designs and real-world evidence strategies to accelerate regulatory engagement and facilitate coverage discussions. Third, align platform selection with realistic manufacturing and distribution pathways. For instance, RNA-based approaches should be matched with cold chain optimization and delivery innovations, whereas viral vector programs require specialized containment and potency testing regimes.

Fourth, pursue targeted collaborations that combine antigen discovery capabilities, delivery expertise, and commercial channel access. These partnerships can accelerate translational timelines while sharing cost and risk. Fifth, engage proactively with regulators and payers through transparent evidence plans, early scientific advice sessions, and value demonstration pilots. Finally, augment commercial readiness with patient-centric access programs, digital adherence tools, and tailored distribution models that reflect the administration route and end-user capabilities. By operationalizing these priorities, industry leaders can convert scientific breakthroughs into durable clinical benefit and sustainable market access.

A transparent and multi-method research approach that integrates literature synthesis, expert interviews, pipeline analysis, and supply chain diagnostics for robust insights

The research methodology underpinning this analysis employed a rigorous, multi-source approach to ensure validity, reliability, and relevance for strategic decision-makers. The process began with a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and industry white papers to establish a baseline understanding of scientific advances and regulatory precedents. This secondary research informed targeted primary engagement, which included structured interviews with clinical investigators, manufacturing experts, regulatory advisors, payer representatives, and supply chain specialists to capture practitioner perspectives and operational constraints.

In parallel, a systematic mapping of technology platforms, manufacturing workflows, and administration routes was conducted to identify critical dependency points and scalability considerations. Clinical pipeline analysis focused on trial design heterogeneity, endpoint selection, and combination therapy strategies, while supply chain diagnostics assessed raw material sourcing, cold chain vulnerabilities, and contract manufacturing capacity. Analytic techniques included thematic synthesis of qualitative data, cross-validation of stakeholder claims against regulatory documents and trial registries, and scenario-based impact assessment to evaluate policy and tariff sensitivities.

Finally, findings were triangulated through iterative expert review and validation sessions to ensure interpretation robustness and practical applicability. This blended methodology balances depth of clinical and technical insight with pragmatic considerations of manufacturing, regulatory, and commercial viability, producing an evidence-informed foundation for the recommendations presented herein.

A conclusive synthesis emphasizing the need to align scientific innovation with manufacturing resilience, payer engagement, and segmented program planning for real-world impact

In conclusion, therapeutic vaccines occupy a pivotal role in the future of precision medicine, offering the prospect of durable disease control across oncology, infectious diseases, autoimmune conditions, and select neurological disorders. Scientific progress in nucleic acid platforms, viral vectors, and cell-based approaches, combined with evolving regulatory pathways and manufacturing innovations, has created a fertile environment for meaningful clinical advances. However, realizing that potential depends on proactive management of supply chain resilience, early alignment with payers and regulators, and careful orchestration of manufacturing and distribution strategies to support diverse administration routes and end-user settings.

Stakeholders who integrate segmented program planning-aligning indication-specific biology with platform capabilities, administration logistics, and distribution channels-will be well-positioned to navigate clinical complexity and access challenges. Moreover, the trade policy shifts witnessed in 2025 underscore the strategic value of supplier diversification and regional manufacturing planning. By coupling scientific rigor with operational foresight and payer-focused evidence generation, developers can translate immunologic innovation into sustainable therapeutic solutions that deliver measurable benefit to patients and health systems alike.

The strategic imperative is clear: to convert technological promise into real-world impact, organizations must synchronize R&D priorities with pragmatic manufacturing investments, adaptive regulatory engagement, and thoughtful market-access planning that ensures therapies reach the patients who need them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of mRNA-based therapeutic vaccine platforms targeting personalized tumor neoantigens to enhance immunogenicity
  • 5.2. Integration of novel adjuvant delivery systems using nanoparticle carriers to boost vaccine-induced immune responses
  • 5.3. Development of combination therapies pairing therapeutic vaccines with immune checkpoint inhibitors to overcome tumor resistance
  • 5.4. Adoption of artificial intelligence in epitope prediction workflows to accelerate vaccine candidate design
  • 5.5. Expansion of off-the-shelf allogeneic dendritic cell vaccines leveraging CRISPR gene editing for antigen loading
  • 5.6. Regulatory pathways evolving for accelerated approval of therapeutic vaccines under IND and BLA frameworks
  • 5.7. Investigation of heterologous prime-boost strategies to improve durability and breadth of vaccine-mediated immunity
  • 5.8. Increasing investment in therapeutic vaccine pipelines from big pharma through strategic biotech partnerships

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Therapeutic Vaccines Market, by Indication

  • 8.1. Autoimmune Diseases
    • 8.1.1. Lupus
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Rheumatoid Arthritis
    • 8.1.4. Type 1 Diabetes
  • 8.2. Cancer
    • 8.2.1. Breast Cancer
    • 8.2.2. Cervical Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Melanoma
    • 8.2.5. Prostate Cancer
  • 8.3. Infectious Diseases
    • 8.3.1. CMV
    • 8.3.2. Hepatitis
    • 8.3.3. HIV
    • 8.3.4. HPV
    • 8.3.5. Influenza
  • 8.4. Neurological Disorders
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Amyotrophic Lateral Sclerosis
    • 8.4.3. Epilepsy
    • 8.4.4. Parkinson's Disease

9. Therapeutic Vaccines Market, by Technology Platform

  • 9.1. Dendritic Cell
  • 9.2. DNA
    • 9.2.1. Plasmid
  • 9.3. Peptide
  • 9.4. RNA
    • 9.4.1. mRNA
    • 9.4.2. Self Amplifying RNA
  • 9.5. Viral Vector
    • 9.5.1. Adenovirus
    • 9.5.2. Lentivirus
    • 9.5.3. Vaccinia Virus
  • 9.6. Whole Cell

10. Therapeutic Vaccines Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Subcutaneous

11. Therapeutic Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Therapeutic Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Therapeutic Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Therapeutic Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Therapeutic Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Moderna, Inc.
    • 16.3.5. BioNTech SE
    • 16.3.6. Bavarian Nordic A/S
    • 16.3.7. Agenus Inc.
    • 16.3.8. Inovio Pharmaceuticals, Inc.
    • 16.3.9. Dendreon Pharmaceuticals LLC
    • 16.3.10. GeoVax Labs, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PLASMID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DNA, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA THE